These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
262 related articles for article (PubMed ID: 3890786)
1. High rate of long-term survival in adult acute leukemia following ten-day chemotherapy (OAP) induction. Maintenance with chemotherapy or chemotherapy plus BCG vaccine. Hewlett JS; Chen T; Balcerzak SP; Gutterman JU; Costanzi JJ; Amare M Arch Intern Med; 1985 Jun; 145(6):1006-12. PubMed ID: 3890786 [TBL] [Abstract][Full Text] [Related]
2. Salvage by timed sequential chemotherapy in primary resistant acute myeloid leukemia: analysis of prognostic factors. Revesz D; Chelghoum Y; Le QH; Elhamri M; Michallet M; Thomas X Ann Hematol; 2003 Nov; 82(11):684-90. PubMed ID: 12928754 [TBL] [Abstract][Full Text] [Related]
3. A randomized, postremission comparison of four courses of standard-dose consolidation therapy without maintenance therapy versus three courses of standard-dose consolidation with maintenance therapy in adults with acute myeloid leukemia: the Japan Adult Leukemia Study Group AML 97 Study. Miyawaki S; Sakamaki H; Ohtake S; Emi N; Yagasaki F; Mitani K; Matsuda S; Kishimoto Y; Miyazaki Y; Asou N; Matsushima T; Takahashi M; Ogawa Y; Honda S; Ohno R; Cancer; 2005 Dec; 104(12):2726-34. PubMed ID: 16284985 [TBL] [Abstract][Full Text] [Related]
4. Alternating pulses of vincristine-prednisone with cytarabine-cyclophosphamide versus vincristine-prednisone in the maintenance therapy of acute lymphoblastic leukemia. Sackmann Muriel F; Svarch E; Pavlovsky S; Bustelo P; Giuntoli J; Vergara B; Garay G; Eppinger-Helft M; Kvicala R; Dibar E Cancer Treat Rep; 1984 Apr; 68(4):581-6. PubMed ID: 6370428 [TBL] [Abstract][Full Text] [Related]
5. Intensive chemotherapy with idarubicin, cytarabine, etoposide, and G-CSF priming in patients with advanced myelodysplastic syndrome and high-risk acute myeloid leukemia. Hofmann WK; Heil G; Zander C; Wiebe S; Ottmann OG; Bergmann L; Hoeffken K; Fischer JT; Knuth A; Kolbe K; Schmoll HJ; Langer W; Westerhausen M; Koelbel CB; Hoelzer D; Ganser A Ann Hematol; 2004 Aug; 83(8):498-503. PubMed ID: 15156346 [TBL] [Abstract][Full Text] [Related]
6. Influence of daunorubicin and cytarabine sequencing on the outcome of therapy in acute myelogenous leukemia: a randomized trial. Archimbaud E; Fiere D; Treille-Ritouet D; Adeleine P; Guyotat D; Sebban C; Vuvan H; Viala JJ Cancer Treat Rep; 1987 Jun; 71(6):571-4. PubMed ID: 3555788 [TBL] [Abstract][Full Text] [Related]
8. Treatment of acute myeloid leukemia in elderly patients: the influence of maintenance therapy (BGM 84 protocol). Montastruc M; Reiffers J; Stoppa AM; Sotto JJ; Corront B; Marit G; Maraninchi D; Michallet M; Gastaut JA; Broustet A Nouv Rev Fr Hematol (1978); 1990; 32(2):147-52. PubMed ID: 2198531 [TBL] [Abstract][Full Text] [Related]
9. OAP combination in the treatment of elderly leukaemic patients with preexisting severe internal disease. Marra R; Pagano L; Liene DR; Storti S; Girasoli M; Leone G Folia Haematol Int Mag Klin Morphol Blutforsch; 1989; 116(2):187-91. PubMed ID: 2475396 [TBL] [Abstract][Full Text] [Related]
10. Results of aggressive chemotherapy for acute nonlymphoblastic leukemia in adults. Armitage JO; Burns CP; Dick FR; Aunan SB; Slymen DJ Cancer Treat Rep; 1982 Nov; 66(11):1917-24. PubMed ID: 7139637 [TBL] [Abstract][Full Text] [Related]
11. [Multicenter randomized control trial on safety of domestic idarubicin for acute leukemia]. Liu Y; Ke XY; Ma J; Shen ZX; Zhang XH; Du X; Zhao YM; Lv JQ; Zhan ZM; Zeng XY; Xu XH; Lu ZS Zhonghua Zhong Liu Za Zhi; 2006 Sep; 28(9):706-8. PubMed ID: 17274381 [TBL] [Abstract][Full Text] [Related]
12. 6-Thioguanine, cytarabine, and daunorubicin (TAD) and high-dose cytarabine and mitoxantrone (HAM) for induction, TAD for consolidation, and either prolonged maintenance by reduced monthly TAD or TAD-HAM-TAD and one course of intensive consolidation by sequential HAM in adult patients at all ages with de novo acute myeloid leukemia (AML): a randomized trial of the German AML Cooperative Group. Büchner T; Hiddemann W; Berdel WE; Wörmann B; Schoch C; Fonatsch C; Löffler H; Haferlach T; Ludwig WD; Maschmeyer G; Staib P; Aul C; Gruneisen A; Lengfelder E; Frickhofen N; Kern W; Serve HL; Mesters RM; Sauerland MC; Heinecke A; J Clin Oncol; 2003 Dec; 21(24):4496-504. PubMed ID: 14673036 [TBL] [Abstract][Full Text] [Related]
13. Adaptive randomized study of idarubicin and cytarabine alone or with interleukin-11 as induction therapy in patients aged 50 or above with acute myeloid leukemia or high-risk myelodysplastic syndromes. Giles FJ; Kantarjian HM; Cortes JE; Faderl S; Verstovsek S; Thomas D; Garcia-Manero G; Wierda W; Ferrajoli A; Kornblau S; Mattiuzzi GN; Tsimberidou AM; Albitar M; O'Brien SM; Estey E Leuk Res; 2005 Jun; 29(6):649-52. PubMed ID: 15863204 [TBL] [Abstract][Full Text] [Related]
14. Time sequential chemotherapy for primary refractory or relapsed adult acute myeloid leukemia: results of the phase II Gemia protocol. Martino R; Guardia R; Altés A; Sureda A; Brunet S; Sierra J Haematologica; 1999 Mar; 84(3):226-30. PubMed ID: 10189387 [TBL] [Abstract][Full Text] [Related]
15. Long-term outcomes of de novo acute myeloid leukemia in Thai patients. Niparuck P; Chuncharunee S; Ungkanont A; Udomtrupayakul U; Aungchaisuksiri P; Rerkamnuatchoke B; Jootar S; Atichartakarn V J Med Assoc Thai; 2009 Sep; 92(9):1143-9. PubMed ID: 19772172 [TBL] [Abstract][Full Text] [Related]
16. Relation between the duration of remission and hyperglycemia during induction chemotherapy for acute lymphocytic leukemia with a hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone/methotrexate-cytarabine regimen. Weiser MA; Cabanillas ME; Konopleva M; Thomas DA; Pierce SA; Escalante CP; Kantarjian HM; O'Brien SM Cancer; 2004 Mar; 100(6):1179-85. PubMed ID: 15022284 [TBL] [Abstract][Full Text] [Related]
17. [Acute myeloid leukemia in those over 70 years of age. Experience using low-dose ara-C treatment]. Rodríguez JN; Fernández-Jurado A; Martino ML; Diéguez JC; Moreno MV; Quesada JA; Polo B; Cañavate M; Amian A; Prados D Sangre (Barc); 1998 Feb; 43(1):35-9. PubMed ID: 9580427 [TBL] [Abstract][Full Text] [Related]
18. Phase II evaluation of an intensified induction therapy with standard daunomycin and cytarabine followed by high dose cytarabine for adults with previously untreated acute myeloid leukemia: a Southwest Oncology Group study (SWOG-9500). Petersdorf SH; Rankin C; Head DR; Terebelo HR; Willman CL; Balcerzak SP; Karnad AB; Dakhil SR; Appelbaum FR Am J Hematol; 2007 Dec; 82(12):1056-62. PubMed ID: 17696203 [TBL] [Abstract][Full Text] [Related]
19. A randomized trial of continuous infusion versus bolus mitoxantrone in combination with cytarabine in newly diagnosed patients with acute myeloblastic leukemia. Koc Y; Oyan B; Kars A; Tekuzman G; Canpinar H; Kansu E Hematol Oncol; 2004 Jun; 22(2):43-53. PubMed ID: 15386563 [TBL] [Abstract][Full Text] [Related]
20. [Short-term intensive consolidation chemotherapy in the treatment of acute nonlymphocytic leukemia]. Nagata K; Abe Y; Hatanaka T; Ito T; Saito M; Ono Y; Kamiya O; Ohara K Gan To Kagaku Ryoho; 1994 Feb; 21(2):231-6. PubMed ID: 8311494 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]